Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Valproate
Treatment for Idiopathic epilepsy
Typical Dosage: 1000-2500 mg daily
Effectiveness
85%
Safety Score
50%
Clinical Trials
2
Participants
75K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
1000-2500 mg daily
Time to Effect
Days to weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$800
Monitoring:$600
Side Effect Mgmt:$500
Total Annual:$1,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$12,667/QALY
QALYs Gained
7.5
Outcome-Based Costs
Cost per Responder
$3,455
Cost per Remission
$4,222
Valproate Outcomes
for Idiopathic epilepsy
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+55%
Remission Rate
+45%
Common Side Effects
Nausea/Vomiting
+15%
Weight gain
+15%
Hair loss
+8%
Tremor
+7%
Sedation
+7%
Hepatotoxicity
+3%
Teratogenicity (major congenital malformations)
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
2 completed trials for Valproate in Idiopathic epilepsy
Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures
NCT03940326COMPLETEDPHASE4
103 participants
INTERVENTIONAL
Sari, Iran
Started: Apr 1, 2018
Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy
NCT06393309COMPLETED
169 participants
OBSERVATIONAL
Sari, Iran
Started: Sep 3, 2022